412 results about "Autoantibody" patented technology

Methods are provided for monitoring treatment of a subject using heparin therapy or a ligand, such as an CD20 or CD52 antibody, that binds to a cellular marker and to which the subject may develop masking reactions or auto-antibodies that inhibit evaluation of treatment. The methods involve adding to a single container a sample containing cells that express the cellular target with (i) a soluble ligand that binds the cellular target, (ii) a soluble ligand that binds the soluble analyte or a competing soluble analyte; and (iii) a capture medium that binds directly to the soluble analyte, indirectly to the soluble analyte, or to the soluble ligand that binds to the soluble analyte. Complexes formed in the container by interaction of these components are substantially simultaneously analyzed and quantitated without physically separating the complexes. Kits for performing the assays are also provided.

The present invention comprises methods and compositions for detecting cancer in an individual comprising autoantibodies to cancer-associated antigens. Specifically, the present invention comprises methods and compositions for detecting autoantibodies to cancer-associated antigen in a bodily fluid as well as use of said autoantibodies as a means to detect the presence of cancer-associated antigens.

The invention discloses a detection method of an aquaporin-4 autoantibody, a fusion expression virus vector and application thereof. The virus vector is pCDH-MCS-AQP4-EF1-copGFP, the nucleotide sequence of which is shown as a sequence table SEQIDNO.2. The invention further discloses application of the fusion expression virus vector in improving the clinical diagnosis and treatment level of ophthalmoneuromyelitis and multiple sclerosis. By adopting immunofluorescent cytochemical staining with higher sensitivity and specificity combined with a flow cytometric detection technology, the AQP-4 antibody is quantitively and qualitatively detection clinically, so that the detection result is more stable, and the labor and the time cost are extremely saved. The project is established to extremely improve the diagnosis and treatment level of ophthalmoneuromyelitis and multiple sclerosis, so that the labor capacity and the living quality of the patient are improved, and huge social and economic benefits are generated.

ITP may be treated using a method that involves identifying the autoimmune response, collecting allogeneic platelets, sterilizing allogeneic platelets and feeding them orally. Auto-antigens contained on the surface of allogeneic platelets administered to the intestines deactivate or delete lymphocytes responsible for auto-antibody production. This treatment can be used for ITP, specifically targets the cause of the disease and provides the possibility of a sustained response without further medication.

The invention generally relates to the field of immunoassays. In particular, the invention relates to use of a calibrator material to calibrate immunoassays for autoantibodies.

The invention provides a kit for detecting an Alzheimer autoantibody in serum. The kit comprises an antigen protein combination, the antigen protein combination contains at least four proteins, and the proteins are selected from RABPT5, RAGE, CRYAB, SRPK1, MAPT, MBP, PLP1, PTCD2, FRMD8, POMC, DNAJC8, CENTA2, HSP60, ADARB1, ASXL1, EDRK, GDF11, P21, CCL2, IL18, VEGF, LENG1 and MRPL34. The inventionfurther provides application of the limited antigen protein combination to preparation of a reagent for detection, diagnosis or risk prediction of Alzheimer, and methods for detection, diagnosis or risk prediction of Alzheimer.

The invention discloses five categories of denaturizing allosteric cyclic citrulline polypeptide, fusion protein, antibodies and a kit thereof, which are formed by synthesizing related antigens that antibodies of rheumatoid arthritis patients can specifically recognize, independent designing amino acid sequences and structures with special derivations, and tests prove that the invention can combine with antibodies in RA blood serum and have better immunity reaction compared with the existing cyclic citrulline polypeptide detections, such as CCP and the like. The polypeptides carry out denaturizing and allosteric design and synthesis according to metabolism of arginine residues, and compared with projects of CCP, C-CRP and RF and the like, the five categories of denaturizing allosteric cyclic citrulline polypeptides are characterized by good specificity, high relevance ratio and high primitive diagnosis rate, etc.

A chemical luminous ligand analysis method for quantitatively checking human antibodies belongs to the biomedical technical field, which comprises: using the generality that staphylococcal protein A (SPA) can react with Fc point of IgG in mice; using the monoclonal antibody of high affinity and specificity to prepare a standard product to establish a standard curve; respectively reacting the monoclonal antibody and the antibody in the sample with enzyme-labeled antigens; using the nanometer magnetic particles coated by SPA as ligand to separate solid and liquid; and using enzymatic chemical illumination reaction catalyzed by horseradish peroxidase (HRP) to process illumination check; thereby establishing a chemical luminous ligand quantitative analysis on human antibodies. The chemical luminous ligand analysis method is suitable for quantitatively checking all human antibodies, for resolving the problem of prior art while most human antibodies can not be accurately and quantitatively checked, avoiding cross reaction and avoiding false negative result or false positive result.

The invention provides a chemiluminescent immunoassay kit for thyroid peroxidase autoantibodies and a preparation method thereof. The invention has the advantages that the reaction pattern of the double antigen sandwich method is adopted, the chemiluminescent technology and the biotin-avidin immune amplifying technological principle are effectively utilized, horse radish peroxidase is adopted to be as the marker enzyme, the content of the thyroid peroxidase autoantibodies in human serum samples is quantitatively detected, and the detection sensitivity can be ensured. The kit of the invention has the advantages of high sensitivity, good repeatability, good stability and high detection efficiency, and can provide a timely and reliable experimental basis for the clinical diagnosis and the treatment of thyroid disorders.

The present invention provides methods of preventing, treating or ameliorating diabetes by administering to a subject in need thereof a therapeutically effective amount of Dll4 antagonists that block Dll4-Notch signal pathways. As observed in a mouse model of diabetes, Dll4 antagonists exhibit protective effects on pancreatic islets, lower blood glucose levels, and block the production of auto-antibodies, including those against insulin and glutamic acid decarboxylase 65 (GAD65), via the expansion of regulatory T cells (Tregs). Thus, the present invention further provides methods of lowering the levels of blood glucose, and/or reducing or blocking the production of auto-antibodies, by administering to a subject in need thereof a therapeutically effective amount of Dll4 antagonists. Suitable Dll4 antagonists for the invention include antibodies or antibody fragments that specifically bind Dll4 and block Dll4-Notch interactions, the extracellular domain of Dll4, and the like.

The invention relates to a test reagent box of multiple antigen membrane method which is used for diagnosing RA, it includes tablets and response groove, the tablets hold on the response groove; the tablets gap corresponding to the response groove gap; there is multi-personal reaction zone on the tablets which correspond with the multi-groove of reaction groove, there is a gap on the top of each groove; membrane bar test paper adhere to each reaction zone and with RA correlate antigen and response control belt; the RA related antigen is the corresponding antigen of RF, anti-CCP, anti-RA-33 antibody, anti-Sa antibody, anti-P68 or more than four kinds of antigen in antigen epitope polypeptide or antigen epitope polypeptide, the response control belt is a mixture of man IgG and man IgM. The reagent box in this invention overcome the lack of detection sensitivity and Specificity of the single autoantibody and the red tape of several autoantibody detection in a single operation, it provide the accuracy and convenience of RA diagnosis. The invention also disclosed the method of how to make the test box.

The invention relates to a method of screening a patient to identify and quantify risk of colorectal cancer, and thereby identify patients suitable for further invasive investigation such as a colonoscopy. The method employs auto-antibodies that are shown to correlate with colorectal cancer risk method and involves of assaying a biological sample from the individual for a combination of a plurality of biomarkers selected from SEQUENCE ID NO's: 1 to 12, where the combination of biomarkers is chosen such that detection of all biomarkers in the patient correlates to at least a 50% risk of the patient being positive for colorectal cancer. Detection of all of the combination of biomarkers indicates that the patient should undergo a colonoscopy. Kits for performing the method of the invention are also provided.

An amino acid sequence for detecting autoantibody of tumor immune marker BIRC5 and an application belong to the technical field of immunology. The invention provides an antigen amino acid sequence of apotosis inhibition gene BIRC5. A BIRC5 polypeptide antigen is used for detecting corresponding specific autoantibody in blood of lung cancer patients, wherein the autoantibody can be used as a tumor marker for evaluating risk of generation of lung cancer. The polypeptide antigen and an antibody thereof can be used for preparing a tumor early-stage diagnosis reagent and developing a targeted drug which is used for treating tumors.

The present invention aims to provide a high-flux fluorescent McAb nanometer microsphere kit which can rapidly, easily and accurately detect platelet antoantibodies so as to make an early diagnosis of autoimmunity diseases, comprising a, a first fluorescent nanometer microsphere solution blocked by the bovine serum albumin and connected with the monoclonal antibody SZ-1; b, a second fluorescent nanometer microsphere solution blocked by the bovine serum albumin and connected with the monoclonal antibody SZ-2; c, a third fluorescent nanometer microsphere solution blocked by the bovine serum albumin and connected with the monoclonal antibody SZ-21; d, a fourth fluorescent nanometer microsphere solution blocked by the bovine serum albumin and connected with the monoclonal antibody SZ-22; e, a fifth fluorescent nanometer microsphere solution blocked by the bovine serum albumin and connected with the monoclonal antibody SZ-51; f, fluorescein isothiocyanate connected goat anti-human polyclonal antibodies; g, a PBS liquid. The invention also provides an application of the kit and a preparation method of main components of the kit.

The presence of certain auto-antibodies indicates that a subject has lupus. The auto-antibodies recognise antigens listed in Table 1 herein. These auto-antibodies and/or the antigens themselves can be used as biomarkers for assessing lupus in a subject.

The presence of certain auto-antibodies indicates that a subject has lupus. The auto-antibodies recognise antigens listed in Table 1 herein. These auto-antibodies and/or the antigens themselves can be used as biomarkers for assessing lupus in a subject.

The invention is directed to an immunotoxin directed at fetal AchR, wherein the immunotoxin may comprises a human Fab fragment based on a human autoantibody or human combinatorial cDNA library and may be a pseudomonas exotoxin A-based single chain Fv IT (35-scFV-ETA). The invention is further directed to method of treating a patient with soft tissue tumour comprising the step of exposing the patient to the immunotoxin of the invention.